Cite
AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes.
MLA
An, Xiaoyu, et al. “AC220 and AraC Cause Differential Inhibitory Dynamics in Patient-Derived M5-AML with FLT3-ITD and, Thus, Ultimately Distinct Therapeutic Outcomes.” Experimental Hematology, vol. 45, Jan. 2017, p. 36–44.e2. EBSCOhost, https://doi.org/10.1016/j.exphem.2016.09.004.
APA
An, X., Liu, J., Wang, N., Wang, D., Huang, L., Zhang, L., Cai, J., Wery, J.-P., Zhou, D., Zhou, J., & Li, Q.-X. (2017). AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes. Experimental Hematology, 45, 36–44.e2. https://doi.org/10.1016/j.exphem.2016.09.004
Chicago
An, Xiaoyu, Jinping Liu, Na Wang, Di Wang, Liang Huang, Likun Zhang, Jie Cai, et al. 2017. “AC220 and AraC Cause Differential Inhibitory Dynamics in Patient-Derived M5-AML with FLT3-ITD and, Thus, Ultimately Distinct Therapeutic Outcomes.” Experimental Hematology 45 (January): 36–44.e2. doi:10.1016/j.exphem.2016.09.004.